Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
31
NCNA Quote, Financials, Valuation and Earnings
Last price:
$3.37
Seasonality move
:
5.34%
Day range:
$3.41 - $3.56
52-week range:
$2.78 - $330.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.68x
Volume:
51K
Avg. volume:
63K
1-year change:
-98.59%
Market cap:
$13.8M
Revenue:
--
EPS (TTM):
-$163.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BCYC
Bicycle Therapeutics Plc
|
$8.2M | -$1.07 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$5M | -$0.00 | -100% | -88.64% | $7.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NCNA
NuCana Plc
|
$3.31 | $104.00 | $13.8M | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics Plc
|
$1.65 | $9.52 | $437.8M | -- | $0.00 | 0% | 8.54x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.93 | $21.50 | $480.7M | -- | $0.00 | 0% | 16.94x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$3.22 | $17.94 | $2.7M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$2.29 | $7.20 | $364.1M | -- | $0.00 | 0% | 715.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 2.129 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 0.598 | 0.12% | 8.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
NuCana Plc vs. Competitors
-
Which has Higher Returns NCNA or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to NuCana Plc's net margin of -373.3%. NuCana Plc's return on equity of -286.82% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About NCNA or AUTL?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 628298.79%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 450.42%. Given that NuCana Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe NuCana Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is NCNA or AUTL More Risky?
NuCana Plc has a beta of 1.595, which suggesting that the stock is 59.472% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock NCNA or AUTL?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or AUTL?
NuCana Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. NuCana Plc's net income of -$378.9K is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, NuCana Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 8.54x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K AUTLAutolus Therapeutics Plc8.54x -- $21.1M -$78.6M
-
Which has Higher Returns NCNA or BCYC?
Bicycle Therapeutics Plc has a net margin of -- compared to NuCana Plc's net margin of -503.67%. NuCana Plc's return on equity of -286.82% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About NCNA or BCYC?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 628298.79%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 199.03%. Given that NuCana Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe NuCana Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is NCNA or BCYC More Risky?
NuCana Plc has a beta of 1.595, which suggesting that the stock is 59.472% more volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.505%.
-
Which is a Better Dividend Stock NCNA or BCYC?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BCYC?
NuCana Plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $11.7M. NuCana Plc's net income of -$378.9K is higher than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, NuCana Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 16.94x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K BCYCBicycle Therapeutics Plc16.94x -- $11.7M -$58.7M
-
Which has Higher Returns NCNA or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to NuCana Plc's net margin of --. NuCana Plc's return on equity of -286.82% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About NCNA or BDRX?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 628298.79%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 5256.97%. Given that NuCana Plc has higher upside potential than Biodexa Pharmaceuticals Plc, analysts believe NuCana Plc is more attractive than Biodexa Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is NCNA or BDRX More Risky?
NuCana Plc has a beta of 1.595, which suggesting that the stock is 59.472% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock NCNA or BDRX?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BDRX?
NuCana Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. NuCana Plc's net income of -$378.9K is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, NuCana Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns NCNA or MREO?
Mereo BioPharma Group Plc has a net margin of -- compared to NuCana Plc's net margin of -2923.31%. NuCana Plc's return on equity of -286.82% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About NCNA or MREO?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 628298.79%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $7.20 which suggests that it could grow by 214.48%. Given that NuCana Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe NuCana Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 MREOMereo BioPharma Group Plc6 0 0 -
Is NCNA or MREO More Risky?
NuCana Plc has a beta of 1.595, which suggesting that the stock is 59.472% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.425%.
-
Which is a Better Dividend Stock NCNA or MREO?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or MREO?
NuCana Plc quarterly revenues are --, which are smaller than Mereo BioPharma Group Plc quarterly revenues of --. NuCana Plc's net income of -$378.9K is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, NuCana Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 715.06x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K MREOMereo BioPharma Group Plc715.06x -- -- -$7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
